Journals / art / 2019 / Cilt: 34 - Sayı: 3

Systemic Lupus Erythematosus and Angioedema: A Cross-Sectional Study From the National Inpatient Sample

Journal
art
Pages
301–307
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SLE is possibly an independent risk factor for AE.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This cross-sectional study aims to investigate the odds of developing angioedema (AE) in systemic lupus erythematosus (SLE) populations compared to non-SLE populations in hospital settings in the United States using a nationwide database.
📊
Key Findings & Data:Materials and methods: We used the data from the National Inpatient Sample for the years 2012 to 2014.
💡
Conclusion & Impact:SLE is possibly an independent risk factor for AE.
🔬Design:Modeling & Simulation
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: This cross-sectional study aims to investigate the odds of developing angioedema (AE) in systemic lupus erythematosus (SLE) populations compared to non-SLE populations in hospital settings in the United States using a nationwide database. Materials and methods: We used the data from the National Inpatient Sample for the years 2012 to 2014. We constructed two models for multivariate logistic regression analysis. Model 1 was designed to adjust demographic information, while model 2 included each factor in model 1 and additionally accounted for AE-related comorbidities. Results: A total of 90,485 hospitalizations with an AE diagnosis were identified for the years 2012 to 2014, among which 1,505 hospitalizations had both SLE and AE. Compared to those without SLE, AE patients with SLE were younger and included more females. In AE hospitalizations, SLE was associated with higher odds of AE-related comorbidities including atopic disorder, leukocytoclastic vasculitis, eosinophilia, and infections. SLE was associated with higher odds of AE both as all inpatient diagnosis and as principal diagnosis (unadjusted odds ratio [OR] 3.24, 95% confidence interval [CI] 2.87-3.63, p<0.001, model 1 adjusted OR 2.54, 95% CI 2.26-2.86, p<0.001, model 2 adjusted OR 1.71, 95% CI 1.51-1.93, p<0.001). Conclusion: Our study demonstrates that SLE is associated with higher odds of having AE, including severe AE as the principal reason for inpatient admission. SLE is possibly an independent risk factor for AE.

🔖

Cite This Article

LUO, Y., FAN, X., JIANG, C., RAMOS-RODRIGUEZ, A., WEN, Y., ZHANG, J., HUANG, F., GUAN, X., XU, J. (2019). Systemic Lupus Erythematosus and Angioedema: A Cross-Sectional Study From the National Inpatient Sample. art, Cilt: 34 - Sayı: 3, 301–307. https://ajindex.com/articles/146366

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Lewis LM. Angioedema: etiology, pathophysiology, current and emerging therapies. J Emerg Med 2013;45:789-96
  2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79
  3. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 2003;49:283-5
  4. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016;12:605-20
  5. Donaldson VH, Hess EV, McAdams AJ. Lupuserythematosus- like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med 1977;86:312-3
  6. Brickman CM, Tsokos GC, Balow JE, Lawley TJ, Santaella M, Hammer CH, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986;77:749-57
  7. Lahiri M, Lim AY. Angioedema and systemic lupus erythematosus--a complementary association? Ann Acad Med Singapore 2007;36:142-5
  8. Thong BY, Thumboo J, Howe HS, Feng PH. Life-threatening angioedema in systemic lupus erythematosus. Lupus 2001;10:304-8
  9. Cacoub P, Frémeaux-Bacchi V, De Lacroix I, Guillien F, Kahn MF, Kazatchkine MD, et al. A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus. Arthritis Rheum 2001;44:1836-40
  10. Tekin ZE, Yener GO, Yüksel S. Acquired angioedema in juvenile systemic lupus erythematosus: case-based review. Rheumatol Int 2018;38:1577-84
  11. Databases H. Healthcare Cost and Utilization Project - Overview of the National (Nationwide) Inpatient Sample (NIS) Agency for Healthcare Research and Quality 2016 Available from: www.hcup-us.ahrq.gov/ nisoverview.jsp
  12. Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. Eff Clin Pract 2002;5:143-51
  13. Altman D, Frist WH. Medicare and Medicaid at 50 Years: Perspectives of Beneficiaries, Health Care Professionals and Institutions, and Policy Makers. JAMA 2015;314:384-95
  14. Sule S, Petri M. Socioeconomic status in systemic lupus erythematosus. Lupus 2006;15:720-3
  15. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011;20:40-9
  16. Hsiao YP, Tsai JD, Muo CH, Tsai CH, Sung FC, Liao YT, et al. Atopic diseases and systemic lupus erythematosus: an epidem